Monique Krystyna van der Kooij

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7068127/publications.pdf Version: 2024-02-01



Monique Krystyna van der

#	Article	IF	CITATIONS
1	Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncológica, 2013, 52, 1786-1788.	1.8	67
2	Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers, 2019, 11, 845.	3.7	58
3	Evolutionary Routes in Metastatic Uveal Melanomas Depend on <i>MBD4</i> Alterations. Clinical Cancer Research, 2019, 25, 5513-5524.	7.0	46
4	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 641-648.	3.9	46
5	Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry. Cancers, 2019, 11, 1007.	3.7	22
6	Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. , 2020, 8, e000166.		17
7	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 2020, 12, 2072.	3.7	16
8	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatology International, 2021, 15, 510-519.	4.2	14
9	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	3.7	9
10	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 1345-1346.	3.9	4
11	Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. BMJ Open, 2020, 10, e044036.	1.9	0